Exploring Personalized Tailored Hemophilia Treatment : Tailoring Treatment to Individual Needs.

초록

Hemophilia management has traditionally focused on preventing and controlling bleeding episodes through standardized prophylaxis and acute care approaches. Recent years have seen a paradigm shift towards personalized medicine, leveraging advancements in genetic testing, pharmacogenomics, and pharmacokinetics to tailor treatment to individual patient needs. With the rapid advancement of medical technologies, the landscape of hemophilia treatment has been dramatically and significantly broadening the array of therapeutic options available to patients. This evolution has paved the way for implementing personalized medicine strategies, which now extend beyond traditional treatments to include extended half-life (EHL) factor VIII and factor IX concentrates, factor VIII-mimicking monoclonal antibodies, agents that rebalance coagulation, and the promising horizon of gene therapy. These innovations not only offer more flexible treatment schedules but also aim to enhance overall patient well-being by maintaining increased trough levels and reducing the frequency of bleeding episodes. However, it remains uncertain which patients will derive the greatest benefit from these new treatment options, as long-term data are still limited. Additionally, it is still unclear how to effectively combine genetic data, pharmacogenetic insights, and pharmacokinetic profiles to optimize personalized prophylaxis in hemophilia treatment. This review explores the integration of these advanced diagnostic and therapeutic options within the framework of personalized medicine, highlighting their potential to tailor treatment plans to the individual characteristics and needs. By reviewing the latest research and clinical trial outcomes, we will assess the impact of these advancements on patient care, discuss the challenges and considerations in their application, and envisage the future directions of hemophilia management.